SINTX TECHNOLOGIES ANNOUNCES SARS-COV-2 TESTING RESULTS
June 20 2020 - 12:57AM
SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”),
an original equipment manufacturer (OEM) ceramics company focused
on silicon nitride and its applications, today announced that in a
controlled laboratory study, the SARS-CoV-2 virus was inactivated
when exposed to SINTX’s sintered silicon nitride powder. The
Company expects to share additional data soon, once the findings
are published in a rapid-review forum.
“The preliminary results are encouraging,” said
Dr. Sonny Bal, CEO of SINTX. “The antiviral data are consistent
with the well-established anti-bacterial properties of SINTX’s
silicon nitride, and with previously reported effectiveness against
several single-strand RNA viruses. Additional testing at
independent, outside laboratories is in progress to corroborate the
effectiveness of silicon nitride against SARS-CoV-2.”
SINTX is committed to the scientific integrity
of its R&D programs and has invested heavily in the careful
verification of its reported findings. No representations are made
as to the effectiveness of silicon nitride in consumer products,
whether medical or otherwise. Investors are cautioned against
making any assumptions based on the experimental results reported
herein.
About SINTX Technologies,
Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes silicon nitride for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of silicon nitride
ceramics for external partners. The Company manufactures silicon
nitride material and components in its FDA registered and ISO 13485
certified facility.
For more information on SINTX
Technologies or its silicon nitride material platform, please visit
www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA) that are subject to a number of risks
and uncertainties. Risks and uncertainties that may cause such
differences include, among other things, the uncertainties inherent
in research and development, including the cost and time required
advance our products to regulatory submission; market acceptance of
our products once cleared and commercialized; our ability to raise
additional funding and other competitive developments. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management’s current estimates, projections,
expectations and beliefs. There can be no assurance that any of the
anticipated results will occur on a timely basis or at all due to
certain risks and uncertainties, a discussion of which can be found
in SINTX’s Risk Factors disclosure in its Annual Report on Form
10-K, filed with the Securities and Exchange Commission (SEC) on
March 26, 2020, and in SINTX’s other filings with the SEC. SINTX
disclaims any obligation to update any forward-looking statements.
SINTX undertakes no obligation to publicly revise or update the
forward-looking statements to reflect events or circumstances that
arise after the date of this report.
Contact:SINTX
Technologies801.839.3502IR@sintx.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Sep 2024 to Oct 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Oct 2023 to Oct 2024